SGPL1
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
07
2019
accepted:
06
08
2019
pubmed:
29
8
2019
medline:
27
7
2021
entrez:
29
8
2019
Statut:
ppublish
Résumé
Sphingosine-1-phosphate (S1P), a sphingolipid with second messenger properties, is a main regulator of various cellular processes including lymphocyte cell trafficking, angiogenesis, cell proliferation, and survival. High S1P concentrations and deficiencies in S1P degradation have been associated with cancer cell progression, their directed chemoattraction and promotion of chemo-resistance mechanism. The endoplasmic reticulum (ER) membrane localized enzyme sphingosine-1-phosphate lyase (SGPL1) has a key role in prevention of S1P overstimulation in tumor cells by its irreversible S1P degradation activity. In this paper we demonstrated a SGPL1 overexpression and mislocalization in pediatric alveolar rhabdomyosarcoma (RMA) cells. Moreover, a homozygous point mutation from A to G at position 321 in the coding sequence was obvious, which interferes with the S1P degradation activity and correct localization in the ER-membrane. By complementation with the native SGPL1 variant, the ER localization was restored in RMA cells. More importantly, the SGPL1 restauration prevents the S1P induced migration and colony formation of RMA cells, significantly. This observation opens new highways for the treatment of pediatric RMA by gene therapeutic SGPL1 renewal and recommends the detection of specific SGPL1 mutations as pathological, molecular metastasis marker.
Identifiants
pubmed: 31455837
doi: 10.1038/s41417-019-0132-8
pii: 10.1038/s41417-019-0132-8
pmc: PMC7445884
doi:
Substances chimiques
Biomarkers, Tumor
0
Lysophospholipids
0
sphingosine 1-phosphate
26993-30-6
Aldehyde-Lyases
EC 4.1.2.-
SGPL1 protein, human
EC 4.1.2.27
Sphingosine
NGZ37HRE42
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-584Références
Fantini J, Garmy N, Mahfoud R, Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimer’s and prion diseases. Expert Rev Mol Med. 2002;4:1–22.
pubmed: 14987385
Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci. 2005;118:4605–12.
pubmed: 16219683
Serra M, Saba JD. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzym Regul. 2010;50:349–62.
Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181–95.
pubmed: 18552276
pmcid: 2695666
Spiegel S, Milstien S. Functions of a new family of sphingosine-1-phosphate receptors. Biochim et Biophys Acta - Mol Cell Biol Lipids. 2000;1484:107–16.
Pitson SM, Powell JA, Bonder CS. Regulation of sphingosine kinase in hematological malignancies and other cancers. Anti-cancer Agents Med Chem. 2011;11:799–809.
Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309:1735–9.
pubmed: 16151014
Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 2007;21:1202–9.
pubmed: 17215483
Berdyshev EV, Gorshkova IA, Garcia JGN, Natarajan V, Hubbard WC. Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. Anal Biochem. 2005;339:129–36.
pubmed: 15766719
Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352:809–15.
pubmed: 11104690
pmcid: 1221521
Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007;282:10922–34.
pubmed: 17303574
Selvam SP, Ogretmen B. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance. Handbook Exp. Pharmacol. 2013;216:3–27.
Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006;20:95–102.
pubmed: 16281067
Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753–63.
pubmed: 18787560
pmcid: 2600775
Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489–503.
pubmed: 20555359
Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol cell Biol. 2003;4:397–407.
pubmed: 12728273
Celià-Terrassa T, Kang Y. Mouse genomic screen reveals novel host regulator of metastasis. Genome Biol. 2017;18:31.
pubmed: 28209174
pmcid: 5314612
Merrill AH. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem. 2002;277:25843–6.
pubmed: 12011104
Pyne NJ, El Buri A, Adams DR, Pyne S. Sphingosine 1-phosphate and cancer. Adv Biol Regul. 2018;68:97–106.
pubmed: 28942351
Pitson SM, Xia P, Leclercq TM, Moretti PAB, Zebol JR, Lynn HE, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 2005;201:49–54.
pubmed: 15623571
pmcid: 2212769
Zhu L, Wang Z, Lin Y, Chen Z, Liu H, Chen Y, et al. Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway. Oncol Rep. 2015;33:1257–63.
pubmed: 25529771
Pan J, Tao Y-F, Zhou Z, Cao B-R, Wu S-Y, Zhang Y-L, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 2011;9:157.
pubmed: 21936950
pmcid: 3186754
Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood. 2005;106:1808–16.
pubmed: 15890687
Meng X-D, Zhou Z-S, Qiu J-H, Shen W-H, Wu Q, Xiao J. Increased SPHK1 expression is associated with poor prognosis in bladder cancer. Tumour Biol. 2014;35:2075–80.
pubmed: 24092575
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D’Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19:138–47.
pubmed: 23166225
Patmanathan SN, Johnson SP, Lai SL, Panja Bernam S, Lopes V, Wei W, et al. Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Sci Rep. 2016;6:25650.
pubmed: 27160553
pmcid: 4861980
Wang F, Wu Z. Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther. Med. 2018;15:5371–6.
pubmed: 29844803
pmcid: 5958821
Bandhuvula P, Saba JD. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol Med. 2007;13:210–7.
pubmed: 17416206
Schneider G, Bryndza E, Abdel-Latif A, Ratajczak J, Maj M, Tarnowski M, et al. Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy. Mol Cancer Res. 2013;11:793–807.
pubmed: 23615526
pmcid: 3720846
Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006;9:225–38.
pubmed: 16530706
Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004;18:551–3.
pubmed: 14715694
Engel N, Adamus A, Frank M, Kraft K, Kühn J, Müller P, et al. First evidence of SGPL1 expression in the cell membrane silencing the extracellular S1P siren in mammary epithelial cells. PLoS ONE. 2018;13:e0196854.
pubmed: 29718989
pmcid: 5931664
van Veldhoven PP. Sphingosine-1-phosphate lyase. Methods Enzymol. 2000;311:244–54.
pubmed: 10563331
Bourquin F, Riezman H, Capitani G, Grütter MG. Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure. 2010;18:1054–65.
pubmed: 20696404
Reiss U, Oskouian B, Zhou J, Gupta V, Sooriyakumaran P, Kelly S, et al. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J Biol Chem. 2004;279:1281–90.
pubmed: 14570870
Kumar A, Oskouian B, Fyrst H, Zhang M, Paris F, Saba JD. S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism. Cell death Dis. 2011;2:e119.
pubmed: 21368890
pmcid: 3101703
Min J, van Veldhoven PP, Zhang L, Hanigan MH, Alexander H, Alexander S. Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Mol Cancer Res. 2005;3:287–96.
pubmed: 15886300
Oskouian B, Sooriyakumaran P, Borowsky AD, Crans A, Dillard-Telm L, Tam YY, et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci USA. 2006;103:17384–9.
pubmed: 17090686
Colié S, van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli S-C, et al. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res. 2009;69:9346–53.
pubmed: 19934311
Engel N, Adamus A, Schauer N, Kühn J, Nebe B, Seitz G, et al. Synergistic Action of Genistein and Calcitriol in Immature Osteosarcoma MG-63 Cells by SGPL1 Up-Regulation. PLoS ONE. 2017;12:e0169742.
pubmed: 28125641
pmcid: 5268493
Engel N, Lisec J, Piechulla B, Nebe B. Metabolic profiling reveals sphingosine-1-phosphate kinase 2 and lyase as key targets of (phyto-) estrogen action in the breast cancer cell line MCF-7 and not in MCF-12A. PLoS ONE. 2012;7:e47833.
pubmed: 23112854
pmcid: 3480432
Koscielniak E, Klingebiel T. German S1-guideline 025/007: Soft Tissue Sarcoma: update 03/2017. AWMF-Register Nr. 025/0077777 Klasse: S1. <http://www.awmf.org/uploads/tx_szleitlinien/025-007l_S1_Weichteilsarkome_2017-03.pdf> .
Wachtel M, Schäfer BW. PAX3-FOXO1: Zooming in on an “undruggable” target. Semin Cancer Biol. 2018;50:115–23.
pubmed: 29146205
Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012;11:1841–51.
pubmed: 22784711
Carney EF. Genetics: SGPL1 mutations cause a novel SRNS syndrome. Nat Rev Nephrol. 2017;13:191.
pubmed: 28218265
Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi W-I, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Investig. 2017;127:912–28.
pubmed: 28165339
Prasad R, Hadjidemetriou I, Maharaj A, Meimaridou E, Buonocore F, Saleem M, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Investig. 2017;127:942–53.
pubmed: 28165343
Hait NC, Sarkar S, Le Stunff H, Mikami A, Maceyka M, Milstien S, et al. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J Biol Chem. 2005;280:29462–9.
pubmed: 15951439
Adamus A, Peer K, Ali I, Lisec J, Falodun A, Frank M, et al. Berberis orthobotrys - A promising herbal anti-tumorigenic candidate for the treatment of pediatric alveolar rhabdomyosarcoma. J Ethnopharmacol. 2019;229:262–71.
pubmed: 30315865
Engel N, Ali I, Adamus A, Frank M, Dad A, Ali S, et al. Antitumor evaluation of two selected Pakistani plant extracts on human bone and breast cancer cell lines. BMC Complement Altern Med. 2016;16:244.
pubmed: 27457235
pmcid: 4960692
Adamus A, Müller P, Nissen B, Kasten A, Timm S, Bauwe H, et al. GCSH antisense regulation determines breast cancer cells’ viability. Sci Rep. 2018;8:15399.
pubmed: 30337557
pmcid: 6193953
Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
pubmed: 17406473
Engel N, Kraft K, Müller P, Duske K, Kühn J, Oppermann C, et al. Actin cytoskeleton reconstitution in MCF-7 breast cancer cells initiated by a native flax root extract. Adv Med Plant Res. 2015;3:92–105.